Industries > Pharma > Pain Management Therapeutics Market Report 2021-2031
Pain Management Therapeutics Market Report 2021-2031
By Drug Class (NSAIDS, Anesthetics, Anticonvulsants, Antimigraine Drug, Antidepressant Drugs, Opioids, and Non-narcotic analgesics), By Indication (Arthritic pain, Neuropathic pain, Cancer pain, Chronic back pain, Post-operative pain, Migraine, Fibromyalgia, Bone fracture, Muscle sprain/strain, Acute appendicitis, and Others), By Drug Type (Generic Drug, and Branded Drug ), By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Leading Regional/ Country market analysis
Pain Management Therapeutics Market– our new study reveals trends, R&D progress, and predicted revenues
Where the Pain Management Therapeutics is market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our 290+ page report provides 400+ tables and 390+ charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Pain Management Therapeutics Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
• Revenue and growth forecasts from 2021 to 2031 for the Global Pain Management Therapeutics Market By Drug Class
• NSAIDS
• Anesthetics
• Anticonvulsants
• Antimigraine Drug
• Antidepressant Drugs
• Opioids
o Oxycodones
o Hydrocodones
o Tramadol
o Others
• Non-narcotic Analgesics
• Revenue and growth forecasts from 2021 to 2031 for the Global Pain Management Therapeutics Market By Indication
• Arthritic Pain
• Neuropathic Pain
• Cancer Pain
• Chronic Back Pain
• Post-Operative Pain
• Migraine
• Fibromyalgia
• Bone Fracture
• Muscle Sprain/Strain
• Acute Appendicitis
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Pain Management Therapeutics Market By Drug Type
• Generic Drug
• Branded Drug
• Revenue and growth forecasts from 2021 to 2031 for the Global Pain Management Therapeutics Market By End User
• Hospitals
• Homecare
• Specialty Clinics
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Pain Management Therapeutics Market By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• Middle East and Africa
o Turkey
o Saudi Arabia
o South Africa
o UAE
o Egypt
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Pain Management Therapeutics Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Pain Management Therapeutics Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Pain Management Therapeutics Market report helps you
In summary, our 290+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Pain Management Therapeutics Market, with forecasts for Get our report today Pain Management Therapeutics Market Forecast 2021-2031: By Drug Class, Indication, Drug Type, End User, Distribution Channel and Leading Regional/ Country market analysis each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Pain Management Therapeutics market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Pain Management Therapeutics Market. Some of the company’s profiled in this report include
• Abbott Laboratories
• Eli Lily And Company
• Endo Health Solutions, Inc. (Endo International Plc.)
• Glaxosmithkline Plc (GSK)
• Johnson & Johnson
• Merck & Co., Inc.
• Mylan N.V.
• Novartis International Ag
• Pfizer Inc.
• Purdue Pharma L.P.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Pain Management Therapeutics Market and leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Pain Management Therapeutics Market Report 2021-2031: By Drug Class (NSAIDS, Anesthetics, Anticonvulsants, Antimigraine Drug, Antidepressant Drugs, Opioids, and Non-narcotic analgesics), By Indication (Arthritic pain, Neuropathic pain, Cancer pain, Chronic back pain, Post-operative pain, Migraine, Fibromyalgia, Bone fracture, Muscle sprain/strain, Acute appendicitis, and Others), By Drug Type (Generic Drug, and Branded Drug ), By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Leading Regional/ Country market analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Pain Management Therapeutics Market
2.1. Pain Management Therapeutics Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Indication Submarkets Definitions
3. Pain Management Therapeutics Market Overview
3.1. Global Pain Management Therapeutics Market Size and Forecast by Region
3.2. Global Pain Management Therapeutics Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing Prevalence of Chronic Diseases around the World
3.3.1.2. Growing number of FDA approvals coupled with launch of new products
3.3.1.3. Growing demand in Emerging economies
3.3.1.4. Increasing geriatric population around the world
3.3.2. Market Restraints
3.3.2.1. Adherence to Stringent Regulatory Norms
3.3.2.2. High Cost of development
3.3.2.3. Product Recall
3.3.3. Opportunities
3.3.3.1. Increasing therapeutic Advancements in Pain Management Therapeutics
3.3.3.2. Huge Untapped Potential in Emerging Markets
3.3.4. Challenges
3.3.4.1. Requirement of high investment for storage and transportation
3.3.4.2. Increasing number of competitor in the market
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Pain Management Therapeutics Market Analysis and Forecast 2021-2031, By Drug Class (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. NSAIDS
4.1.1.1. NSAIDS market size and forecast, 2021-2031 (USD Million)
4.1.2. Anesthetics
4.1.2.1. Anesthetics market size and forecast, 2021-2031 (USD Million)
4.1.3. Anticonvulsants
4.1.3.1. Anticonvulsants market size and forecast, 2021-2031 (USD Million)
4.1.4. Antimigraine Drug
4.1.4.1. Antimigraine Drug market size and forecast, 2021-2031 (USD Million)
4.1.5. Antidepressant Drugs
4.1.5.1. Antidepressant Drugs market size and forecast, 2021-2031 (USD Million)
4.1.6. Opioids
4.1.6.1. Opioids market size and forecast, 2021-2031 (USD Million)
4.1.7. Non-narcotic Analgesics
4.1.7.1. Non-narcotic Analgesics market size and forecast, 2021-2031 (USD Million)
4.1.8. Others
4.1.8.1. Others market size and forecast, 2021-2031 (USD Million)
5. Global Pain Management Therapeutics Market Analysis and Forecast, 2021-2031 By Indication (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Arthritic Pain
5.1.1.1. Arthritic Pain market size and forecast, 2021-2031 (USD Million)
5.1.2. Neuropathic Pain
5.1.2.1. Neuropathic Pain market size and forecast, 2021-2031 (USD Million)
5.1.3. Cancer Pain
5.1.3.1. Cancer Pain market size and forecast, 2021-2031 (USD Million)
5.1.4. Chronic back Pain
5.1.4.1. Chronic back Pain market size and forecast, 2021-2031 (USD Million)
5.1.5. Post-operative Pain
5.1.5.1. Post-operative Pain market size and forecast, 2021-2031 (USD Million)
5.1.6. Migraine
5.1.6.1. Migraine market size and forecast, 2021-2031 (USD Million)
5.1.7. Fibromyalgia
5.1.7.1. Fibromyalgia market size and forecast, 2021-2031 (USD Million)
5.1.8. Bone fracture
5.1.8.1. Bone fracture market size and forecast, 2021-2031 (USD Million)
5.1.9. Muscle sprain/strain
5.1.9.1. Muscle sprain/strain market size and forecast, 2021-2031 (USD Million)
5.1.10. Acute appendicitis
5.1.10.1. Acute appendicitis market size and forecast, 2021-2031 (USD Million)
5.1.11. Others
5.1.11.1. Others market size and forecast, 2021-2031 (USD Million)
6. Global Pain Management Therapeutics Market Analysis and Forecast, 2021-2031 By Drug Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Generic drugs
6.1.1.1. Generic drugs market size and forecast, 2021-2031 (USD Million)
6.1.2. Branded Drugs
6.1.2.1. Branded Drugs market size and forecast, 2021-2031 (USD Million)
7. Global Pain Management Therapeutics Market Analysis and Forecast, 2021-2031 by End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Hospitals
7.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
7.1.2. Homecare
7.1.2.1. Homecare market size and forecast, 2021-2031 (USD Million)
7.1.3. Specialty Clinics
7.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
7.1.4. Others
7.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
8. Global Pain Management Therapeutics Market Analysis and Forecast, 2021-2031 by Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Hospitals Pharmacy
8.1.1.1. Hospitals Pharmacy Market size and forecast, 2021-2031 (USD Million)
8.1.2. Retail Pharmacy
8.1.2.1. Retail Pharmacy market size and forecast, 2021-2031 (USD Million)
8.1.3. Ecommerce
8.1.3.1. Ecommerce market size and forecast, 2021-2031 (USD Million)
8.1.4. Others
8.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
9. North America Pain Management Therapeutics Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. North America Pain Management Therapeutics Market Size and Forecast By Drug Class
9.2.1.1. XX Driving/Opportunity Factor
9.2.1.2. XX Driving/Opportunity Factor
9.3. North America Pain Management Therapeutics Market Size and Forecast By Indication
9.3.1.1. XX Driving/Opportunity Factor
9.3.1.2. XX Driving/Opportunity Factor
9.4. North America Pain Management Therapeutics Market Size and Forecast By Drug Type
9.4.1.1. XX Driving/Opportunity Factor
9.4.1.2. XX Driving/Opportunity Factor
9.5. North America Pain Management Therapeutics Market Size and Forecast By End-User
9.5.1.1. XX Driving/Opportunity Factor
9.5.1.2. XX Driving/Opportunity Factor
9.6. North America Pain Management Therapeutics Market Size and Forecast By Distribution Channel
9.6.1.1. XX Driving/Opportunity Factor
9.6.1.2. XX Driving/Opportunity Factor
9.7. U.S. Pain Management Therapeutics Market
9.7.1.1. XX Driving/Opportunity Factor
9.7.1.2. XX Driving/Opportunity Factor
9.8. Canada Pain Management Therapeutics Market
9.8.1.1. XX Driving/Opportunity Factor
9.8.1.2. XX Driving/Opportunity Factor
10. Europe Pain Management Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Europe Pain Management Therapeutics Market Size and Forecast By Drug Class
10.2.1.1. XX Driving/Opportunity Factor
10.2.1.2. XX Driving/Opportunity Factor
10.3. Europe Pain Management Therapeutics Market Size and Forecast By Indication
10.3.1.1. XX Driving/Opportunity Factor
10.3.1.2. XX Driving/Opportunity Factor
10.4. Europe Pain Management Therapeutics Market Size and Forecast By Drug Type
10.4.1.1. XX Driving/Opportunity Factor
10.4.1.2. XX Driving/Opportunity Factor
10.5. Europe Pain Management Therapeutics Market Size and Forecast By End-User
10.5.1.1. XX Driving/Opportunity Factor
10.5.1.2. XX Driving/Opportunity Factor
10.6. Europe Pain Management Therapeutics Market Size and Forecast By Distribution Channel
10.6.1.1. XX Driving/Opportunity Factor
10.6.1.2. XX Driving/Opportunity Factor
10.7. UK Pain Management Therapeutics Market
10.7.1.1. XX Driving/Opportunity Factor
10.7.1.2. XX Driving/Opportunity Factor
10.8. Germany Pain Management Therapeutics Market
10.8.1.1. XX Driving/Opportunity Factor
10.8.1.2. XX Driving/Opportunity Factor
10.9. France Pain Management Therapeutics Market
10.9.1.1. XX Driving/Opportunity Factor
10.9.1.2. XX Driving/Opportunity Factor
10.10. Rest of Europe Pain Management Therapeutics Market
10.10.1.1. XX Driving/Opportunity Factor
10.10.1.2. XX Driving/Opportunity Factor
11. Asia Pacific Pain Management Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. Asia-Pacific Pain Management Therapeutics Market Size and Forecast By Drug Class
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. Asia-Pacific Pain Management Therapeutics Market Size and Forecast By Indication
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. Asia-Pacific Pain Management Therapeutics Market Size and Forecast By Drug Type
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. Asia-Pacific Pain Management Therapeutics Market Size and Forecast By End-User
11.5.1.1. XX Driving/Opportunity Factor
11.5.1.2. XX Driving/Opportunity Factor
11.6. Asia-Pacific Pain Management Therapeutics Market Size and Forecast By Distribution Channel
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. China Pain Management Therapeutics Market
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. India Pain Management Therapeutics Market
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
11.9. Japan Pain Management Therapeutics Market
11.9.1.1. XX Driving/Opportunity Factor
11.9.1.2. XX Driving/Opportunity Factor
11.10. Rest of Asia Pacific Pain Management Therapeutics Market
11.10.1.1. XX Driving/Opportunity Factor
11.10.1.2. XX Driving/Opportunity Factor
12. Latin America Pain Management Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. Latin America Pain Management Therapeutics Market Size and Forecast By Drug Class
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. Latin America Pain Management Therapeutics Market Size and Forecast By Indication
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. Latin America Pain Management Therapeutics Market Size and Forecast By Drug Type
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. Latin America Pain Management Therapeutics Market Size and Forecast By End-User
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. Latin America Pain Management Therapeutics Market Size and Forecast By Distribution Channel
12.7. Brazil Pain Management Therapeutics Market
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. Mexico Pain Management Therapeutics Market
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. Rest of Latin America Pain Management Therapeutics Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
13. MEA Pain Management Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. MEA Pain Management Therapeutics Market Size and Forecast By Drug Class
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. MEA Pain Management Therapeutics Market Size and Forecast By Indication
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. MEA Pain Management Therapeutics Market Size and Forecast By Drug Type
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. MEA Pain Management Therapeutics Market Size and Forecast By End-User
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. MEA Pain Management Therapeutics Market Size and Forecast By Distribution Channel
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. GCC Pain Management Therapeutics Market
13.7.1.1. XX Driving/Opportunity Factor
13.7.1.2. XX Driving/Opportunity Factor
13.8. South Africa Pain Management Therapeutics Market
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. Rest of MEA Pain Management Therapeutics Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
14. Companies in the Pain Management Therapeutics Market
14.1. Abbott Laboratories
14.1.1. Company Snapshot
14.1.2. Company Overview
14.1.3. Financial Performance (2015-2019)
14.1.3.1. Net Revenue
14.1.3.2. Gross Profit
14.1.3.3. Geographical Revenue, 2019
14.1.4. Product Offerings
14.1.5. Recent Initiatives (2017-2019)
14.2. Eli Lily And Company
14.2.1. Company Snapshot
14.2.2. Company Overview
14.2.3. Financial Performance (2015-2019)
14.2.3.1. Net Revenue
14.2.3.2. Gross Profit
14.2.3.3. Geographical Revenue, 2019
14.2.4. Product Offerings
14.2.5. Recent Initiatives (2017-2019)
14.3. Endo Health Solutions, Inc. (Endo International Plc.)
14.3.1. Company Snapshot
14.3.2. Company Overview
14.3.3. Financial Performance (2015-2019)
14.3.3.1. Net Revenue
14.3.3.2. Gross Profit
14.3.3.3. Geographical Revenue, 2019
14.3.4. Product Offerings
14.3.5. Recent Initiatives (2017-2019)
14.4. Glaxosmithkline Plc (GSK)
14.4.1. Company Snapshot
14.4.2. Company Overview
14.4.3. Financial Performance (2015-2019)
14.4.3.1. Net Revenue
14.4.3.2. Gross Profit
14.4.3.3. Geographical Revenue, 2019
14.4.4. Product Offerings
14.4.5. Recent Initiatives (2017-2019)
14.5. Johnson & Johnson
14.5.1. Company Snapshot
14.5.2. Company Overview
14.5.3. Financial Performance (2015-2019)
14.5.3.1. Net Revenue
14.5.3.2. Gross Profit
14.5.3.3. Geographical Revenue, 2019
14.5.4. Product Offerings
14.5.5. Recent Initiatives (2017-2019)
14.6. Merck & Co., Inc.
14.6.1. Company Snapshot
14.6.2. Company Overview
14.6.3. Financial Performance (2015-2019)
14.6.3.1. Net Revenue
14.6.3.2. Gross Profit
14.6.3.3. Geographical Revenue, 2019
14.6.4. Product Offerings
14.6.5. Recent Initiatives (2017-2019)
14.7. Mylan N.V.
14.7.1. Company Snapshot
14.7.2. Company Overview
14.7.3. Financial Performance (2015-2019)
14.7.3.1. Net Revenue
14.7.3.2. Gross Profit
14.7.3.3. Geographical Revenue, 2019
14.7.4. Product Offerings
14.7.5. Recent Initiatives (2017-2019)
14.8. Merck & Co.
14.8.1. Company Snapshot
14.8.2. Company Overview
14.8.3. Financial Performance (2015-2019)
14.8.3.1. Net Revenue
14.8.3.2. Gross Profit
14.8.3.3. Geographical Revenue, 2019
14.8.4. Product Offerings
14.8.5. Recent Initiatives (2017-2019)
14.9. Novartis
14.9.1. Company Snapshot
14.9.2. Company Overview
14.9.3. Financial Performance (2015-2019)
14.9.3.1. Net Revenue
14.9.3.2. Gross Profit
14.9.3.3. Geographical Revenue, 2019
14.9.4. Product Offerings
14.9.5. Recent Initiatives (2017-2019)
14.10. Pfizer
14.10.1. Company Snapshot
14.10.2. Company Overview
14.10.3. Financial Performance (2015-2019)
14.10.3.1. Net Revenue
14.10.3.2. Gross Profit
14.10.3.3. Geographical Revenue, 2019
14.10.4. Product Offerings
14.10.5. Recent Initiatives (2017-2019)
14.11. Other Notable Players
15. Conclusion
16. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Pain Management Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Pain Management Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Pain Management Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Pain Management Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Pain Management Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Pain Management Therapeutics Market Drivers & Restraints 2021
Table 7. Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. NSAIDS Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. NSAIDS Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. NSAIDS Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. NSAIDS Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. NSAIDS Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Anesthetics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Anesthetics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Anesthetics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Anesthetics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Anesthetics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Anticonvulsants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Anticonvulsants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Anticonvulsants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Anticonvulsants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Anticonvulsants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Antimigraine Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Antimigraine Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Antimigraine Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Antimigraine Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Antimigraine Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Antidepressant Drugs Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 33. Antidepressant Drugs Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Antidepressant Drugs Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Antidepressant Drugs Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Antidepressant Drugs Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Non-narcotic Analgesics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Non-narcotic Analgesics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Non-narcotic Analgesics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Non-narcotic Analgesics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Non-narcotic Analgesics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Arthritic PainForecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Arthritic PainForecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Arthritic PainForecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Arthritic PainForecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Arthritic PainForecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Neuropathic Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Neuropathic Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Neuropathic Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Neuropathic Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Neuropathic Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Cancer Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Cancer Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Cancer Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Cancer Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Cancer Pain h Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Chronic back Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Chronic back Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Chronic back Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Chronic back Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Chronic back Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Post-operative Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Post-operative Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Post-operative Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Post-operative Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Post-operative Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Migraine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Migraine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Migraine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Migraine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Migraine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Fibromyalgia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Fibromyalgia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Fibromyalgia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Fibromyalgia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Fibromyalgia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Bone Fracture Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Bone Fracture Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Bone Fracture Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Bone Fracture Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Bone Fracture Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Muscle Sprain/Strain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Muscle Sprain/Strain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Muscle Sprain/Strain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Muscle Sprain/Strain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Muscle Sprain/Strain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L) Acute Appendicitis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 97. Acute Appendicitis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 98. Acute Appendicitis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 99. Acute Appendicitis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 100. Acute Appendicitis h Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 101. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 102. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 103. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 104. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 105. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 106. Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 107. Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 108. Pain Management Therapeutics Market Forecast by Drug Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 109. Pain Management Therapeutics Market Forecast by Drug Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 110. Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 111. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 112. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 113. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 114. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 115. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 116. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 117. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 118. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 119. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 120. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 121. Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 122. Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 123. Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 124. Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 125. Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 126. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 127. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 128. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 129. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 130. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 131. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 132. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 133. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 134. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 135. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 136. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 137. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 138. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 139. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 140. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 141. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 142. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 143. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 144. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 145. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 146. Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 147. Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 148. Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 149. Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 150. Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 151. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 152. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 153. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 154. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 155. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 156. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 157. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 158. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 159. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 160. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 161. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 162. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 163. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 164. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 165. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 166. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 167. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 168. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 169. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 170. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 171. North America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 172. North America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 173. North America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 174. North America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 175. North America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 176. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 177. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 178. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 179. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 180. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 181. North America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 182. North America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 183. North America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 184. North America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 185. North America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 186. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 187. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 188. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 189. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 190. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 191. North America Pain Management Therapeutics Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 192. North America Pain Management Therapeutics Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 193. North America Pain Management Therapeutics Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 194. North America Pain Management Therapeutics Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 195. North America Pain Management Therapeutics Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 196. North America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 197. North America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 198. North America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 199. North America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 200. North America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 201. North America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 202. North America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 203. North America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 204. North America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 205. North America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 206. North America Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 207. North America Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 208. North America Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 209. North America Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 210. North America Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 211. US Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 212. US Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 213. US Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 214. US Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 215. US Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 216. Canada Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 217. Canada Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 218. Canada Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 219. Canada Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 220. Canada Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 221. Europe Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 222. Europe Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 223. Europe Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 224. Europe Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 225. Europe Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 226. Europe Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 227. Europe Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 228. Europe Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 229. Europe Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 230. Europe Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 231. Europe Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 232. Europe Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 233. Europe Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 234. Europe Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 235. Europe Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 236. Europe Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 237. Europe Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 238. Europe Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 239. Europe Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 240. Europe Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 241. Europe Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 242. Europe Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 243. Europe Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 244. Europe Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 245. Europe Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 246. Europe Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 247. Europe Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 248. Europe Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 249. Europe Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 250. UK Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 251. UK Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 252. UK Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 253. UK Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 254. UK Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 255. Germany Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 256. Germany Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 257. Germany Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 258. Germany Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 259. Germany Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 260. France Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 261. France Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 262. France Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 263. France Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 264. France Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 265. Rest of Europe Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 266. Rest of Europe Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 267. Rest of Europe Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 268. Rest of Europe Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 269. Rest of Europe Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 270. Asia Pacific Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 271. Asia Pacific Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 272. Asia Pacific Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 273. Asia Pacific Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 274. Asia Pacific Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 275. Asia Pacific Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 276. Asia Pacific Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 277. Asia Pacific Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 278. Asia Pacific Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 279. Asia Pacific Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 280. Asia Pacific Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 281. Asia Pacific Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 282. Asia Pacific Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 283. Asia Pacific Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 284. Asia Pacific Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 285. Asia Pacific Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 286. Asia Pacific Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 287. Asia Pacific Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 288. Asia Pacific Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 289. Asia Pacific Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 290. Asia Pacific Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 291. Asia Pacific Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 292. Asia Pacific Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 293. Asia Pacific Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 294. Asia Pacific Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 295. Asia Pacific Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 296. Asia Pacific Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 297. Asia Pacific Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 298. Asia Pacific Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 299. Asia Pacific Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 300. China Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 301. China Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 302. China Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 303. China Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 304. China Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 305. India Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 306. India Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 307. India Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 308. India Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 309. India Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 310. Japan Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 311. Japan Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 312. Japan Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 313. Japan Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 314. Japan Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 315. RoAPAC Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 316. RoAPAC Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 317. RoAPAC Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 318. RoAPAC Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 319. RoAPAC Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 320. Middle East Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 321. Middle East Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 322. Middle East Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 323. Middle East Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 324. Middle East Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 325. Middle East Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 326. Middle East Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 327. Middle East Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 328. Middle East Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 329. Middle East Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 330. Middle East Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 331. Middle East Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 332. Middle East Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 333. Middle East Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 334. Middle East Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 335. Middle East Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 336. Middle East Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 337. Middle East Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 338. Middle East Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 339. Middle East Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 340. Middle East Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 341. Middle East Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 342. Middle East Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 343. Middle East Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 344. Middle East Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 345. Latin America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 346. Latin America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 347. Latin America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 348. Latin America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 349. Latin America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 350. Latin America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 351. Latin America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 352. Latin America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 353. Latin America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 354. Latin America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 355. Latin America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 356. Latin America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 357. Latin America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 358. Latin America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 359. Latin America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 360. Latin America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 361. Latin America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 362. Latin America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 363. Latin America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 364. Latin America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 365. Latin America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 366. Latin America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 367. Latin America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 368. Latin America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 369. Latin America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 370. Africa Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 371. Africa Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 372. Africa Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 373. Africa Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 374. Africa Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 375. Africa Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 376. Africa Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 377. Africa Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 378. Africa Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 379. Africa Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 380. Africa Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 381. Africa Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 382. Africa Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 383. Africa Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 384. Africa Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 385. Africa Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 386. Africa Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 387. Africa Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 388. Africa Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 389. Africa Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 390. Africa Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 391. Africa Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 392. Africa Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 393. Africa Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 394. Africa Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 395. Leading 10 Pain Management Therapeutics Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 396. Abbott Laboratories Profile 2019 (CEO, HQ, Founded, Website)
Table 397. Abbott Laboratories Pain Management Therapeutics Product Offering (Segment, Product Offerings)
Table 398. Eli Lily And Company Profile 2019 (CEO, HQ, Founded, Website)
Table 399. Eli Lily And Company Pain Management Therapeutics Product Offering (Segment, Product Offerings)
Table 400. Endo Health Solutions, Inc. (Endo International Plc.) Profile 2019 (CEO, HQ, Founded, Website)
Table 401. Endo Health Solutions, Inc. (Endo International Plc.).Pain Management Therapeutics Product Offering (Segment, Product Offerings)
Table 402. Glaxosmithkline Plc (GSK) Profile 2019 (CEO, HQ, Founded, Website)
Table 403. Glaxosmithkline Plc (GSK) Pain Management Therapeutics Product Offering (Segment, Product Offerings)
Table 404. Johnson & Johnson Profile 2019 (CEO, HQ, Founded, Website)
Table 405. Johnson & Johnson Pain Management Therapeutics Product Offering (Segment, Product Offerings)
Table 406. Merck & Co., Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 407. Merck & Co., Inc. Pain Management Therapeutics Product Offering (Segment, Product Offerings)
Table 408. GlaxoSmithKline (GSK) Profile 2019 (CEO, HQ, Founded, Website)
Table 409. GlaxoSmithKline (GSK) Pain Management Therapeutics Product Offering (Segment, Product Offerings)
Table 410. Mylan N.V. Profile 2019 (CEO, HQ, Founded, Website)
Table 411. Mylan N.V Pain Management Therapeutics Product Offering (Segment, Product Offerings)
Table 412. Novartis Profile 2019 (CEO, HQ, Founded, Website)
Table 413. Novartis Pain Management Therapeutics Product Offering (Segment, Product Offerings)
Table 414. Pfizer Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 415. Pfizer Corporation Pain Management Therapeutics Product Offering (Segment, Product Offerings)
Table 416. Other Companies Involved in the Pain Management Therapeutics Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Pain Management Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Pain Management Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Pain Management Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Pain Management Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Pain Management Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Pain Management Therapeutics Market Drivers & Restraints 2021
Figure 7. Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. NSAIDS Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. NSAIDS Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. NSAIDS Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. NSAIDS Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. NSAIDS Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Anesthetics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Anesthetics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Anesthetics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Anesthetics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Anesthetics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Anticonvulsants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Anticonvulsants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Anticonvulsants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Anticonvulsants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Anticonvulsants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Antimigraine Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Antimigraine Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Antimigraine Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Antimigraine Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Antimigraine Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Antidepressant Drugs Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 33. Antidepressant Drugs Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Antidepressant Drugs Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Antidepressant Drugs Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Antidepressant Drugs Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Non-narcotic Analgesics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Non-narcotic Analgesics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Non-narcotic Analgesics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Non-narcotic Analgesics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Non-narcotic Analgesics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Arthritic PainForecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Arthritic PainForecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Arthritic PainForecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Arthritic PainForecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Arthritic PainForecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Neuropathic Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Neuropathic Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Neuropathic Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Neuropathic Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Neuropathic Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Cancer Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Cancer Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Cancer Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Cancer Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Cancer Pain h Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Chronic back Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Chronic back Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Chronic back Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Chronic back Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Chronic back Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Post-operative Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Post-operative Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Post-operative Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Post-operative Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Post-operative Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Migraine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Migraine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Migraine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Migraine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Migraine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Fibromyalgia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Fibromyalgia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Fibromyalgia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Fibromyalgia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Fibromyalgia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Bone Fracture Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Bone Fracture Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Bone Fracture Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Bone Fracture Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Bone Fracture Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Muscle Sprain/Strain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Muscle Sprain/Strain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Muscle Sprain/Strain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Muscle Sprain/Strain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Muscle Sprain/Strain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L) Acute Appendicitis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 97. Acute Appendicitis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 98. Acute Appendicitis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 99. Acute Appendicitis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 100. Acute Appendicitis h Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 101. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 102. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 103. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 104. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 105. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 106. Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 107. Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 108. Pain Management Therapeutics Market Forecast by Drug Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 109. Pain Management Therapeutics Market Forecast by Drug Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 110. Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 111. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 112. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 113. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 114. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 115. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 116. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 117. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 118. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 119. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 120. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 121. Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 122. Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 123. Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 124. Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 125. Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 126. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 127. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 128. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 129. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 130. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 131. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 132. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 133. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 134. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 135. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 136. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 137. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 138. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 139. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 140. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 141. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 142. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 143. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 144. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 145. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 146. Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 147. Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 148. Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 149. Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 150. Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 151. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 152. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 153. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 154. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 155. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 156. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 157. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 158. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 159. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 160. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 161. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 162. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 163. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 164. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 165. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 166. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 167. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 168. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 169. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 170. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 171. North America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 172. North America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 173. North America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 174. North America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 175. North America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 176. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 177. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 178. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 179. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 180. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 181. North America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 182. North America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 183. North America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 184. North America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 185. North America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 186. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 187. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 188. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 189. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 190. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 191. North America Pain Management Therapeutics Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 192. North America Pain Management Therapeutics Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 193. North America Pain Management Therapeutics Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 194. North America Pain Management Therapeutics Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 195. North America Pain Management Therapeutics Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 196. North America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 197. North America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 198. North America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 199. North America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 200. North America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 201. North America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 202. North America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 203. North America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 204. North America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 205. North America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 206. North America Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 207. North America Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 208. North America Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 209. North America Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 210. North America Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 211. US Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 212. US Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 213. US Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 214. US Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 215. US Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 216. Canada Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 217. Canada Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 218. Canada Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 219. Canada Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 220. Canada Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 221. Europe Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 222. Europe Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 223. Europe Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 224. Europe Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 225. Europe Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 226. Europe Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 227. Europe Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 228. Europe Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 229. Europe Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 230. Europe Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 231. Europe Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 232. Europe Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 233. Europe Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 234. Europe Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 235. Europe Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 236. Europe Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 237. Europe Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 238. Europe Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 239. Europe Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 240. Europe Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 241. Europe Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 242. Europe Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 243. Europe Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 244. Europe Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 245. Europe Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 246. Europe Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 247. Europe Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 248. Europe Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 249. Europe Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 250. UK Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 251. UK Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 252. UK Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 253. UK Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 254. UK Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 255. Germany Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 256. Germany Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 257. Germany Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 258. Germany Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 259. Germany Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 260. France Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 261. France Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 262. France Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 263. France Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 264. France Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 265. Rest of Europe Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 266. Rest of Europe Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 267. Rest of Europe Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 268. Rest of Europe Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 269. Rest of Europe Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 270. Asia Pacific Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 271. Asia Pacific Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 272. Asia Pacific Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 273. Asia Pacific Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 274. Asia Pacific Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 275. Asia Pacific Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 276. Asia Pacific Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 277. Asia Pacific Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 278. Asia Pacific Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 279. Asia Pacific Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 280. Asia Pacific Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 281. Asia Pacific Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 282. Asia Pacific Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 283. Asia Pacific Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 284. Asia Pacific Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 285. Asia Pacific Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 286. Asia Pacific Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 287. Asia Pacific Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 288. Asia Pacific Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 289. Asia Pacific Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 290. Asia Pacific Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 291. Asia Pacific Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 292. Asia Pacific Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 293. Asia Pacific Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 294. Asia Pacific Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 295. Asia Pacific Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 296. Asia Pacific Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 297. Asia Pacific Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 298. Asia Pacific Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 299. Asia Pacific Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 300. China Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 301. China Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 302. China Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 303. China Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 304. China Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 305. India Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 306. India Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 307. India Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 308. India Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 309. India Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 310. Japan Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 311. Japan Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 312. Japan Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 313. Japan Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 314. Japan Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 315. RoAPAC Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 316. RoAPAC Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 317. RoAPAC Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 318. RoAPAC Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 319. RoAPAC Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 320. Middle East Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 321. Middle East Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 322. Middle East Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 323. Middle East Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 324. Middle East Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 325. Middle East Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 326. Middle East Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 327. Middle East Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 328. Middle East Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 329. Middle East Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 330. Middle East Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 331. Middle East Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 332. Middle East Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 333. Middle East Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 334. Middle East Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 335. Middle East Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 336. Middle East Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 337. Middle East Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 338. Middle East Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 339. Middle East Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 340. Middle East Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 341. Middle East Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 342. Middle East Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 343. Middle East Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 344. Middle East Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 345. Latin America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 346. Latin America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 347. Latin America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 348. Latin America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 349. Latin America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 350. Latin America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 351. Latin America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 352. Latin America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 353. Latin America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 354. Latin America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 355. Latin America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 356. Latin America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 357. Latin America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 358. Latin America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 359. Latin America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 360. Latin America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 361. Latin America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 362. Latin America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 363. Latin America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 364. Latin America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 365. Latin America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 366. Latin America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 367. Latin America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 368. Latin America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 369. Latin America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 370. Africa Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 371. Africa Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 372. Africa Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 373. Africa Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 374. Africa Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 375. Africa Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 376. Africa Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 377. Africa Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 378. Africa Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 379. Africa Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 380. Africa Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 381. Africa Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 382. Africa Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 383. Africa Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 384. Africa Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 385. Africa Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 386. Africa Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 387. Africa Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 388. Africa Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 389. Africa Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 390. Africa Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 391. Africa Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 392. Africa Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 393. Africa Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 394. Africa Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 395.
Figure 396. Porter’s Five Force Analysis
Companies Mentioned
1. AbbVie
2. Achaogen
3. Actavis
4. Actelion
5. Affinium Pharmaceutical
6. AiCuris GmbH & Co. KG
7. Alcon
8. Alkem Laboratories
9. Allergan
10. Allied Pharma
11. Apotex
12. APP Pharmaceuticals
13. Aptalis Pharma
14. Aquapharm Biodiscovery
15. Cempra Pharmaceuticals
16. Cipla
17. Claris Lifesciences
18. Cornerstone Biopharma
19. Cornerstone Therapeutics
20. Corona Remedies
21. Eli Lilly
22. Gate Pharma
23. Gilead Sciences
24. GlaxoSmithKline (GSK)
25. Glenmark
26. GlycoVaxyn
27. Hetero
28. Hikma Farmaceutica
29. Hi-Tech Pharma
30. Hospira
31. Macleod Pharmaceuticals
32. Microlabs
33. Nalneva
34. Novartis
35. Novexel
36. Paratek Pharmaceuticals
37. Pfizer
38. Ranbaxy
39. Roche
40. Sagent Pharmaceuticals
41. Sandoz
42. Sanofi
43. Sequella
44. Shanghai MengKe Pharmaceuticals
45. Shionogi
46. SHIONOGI Co., Ltd.
47. Shire
48. Sidmak Labs
49. Solitaire Pharmacia
50. Specialised Therapeutics Australia
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Pain Management Therapeutics Market
2.1. Pain Management Therapeutics Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Indication Submarkets Definitions
3. Pain Management Therapeutics Market Overview
3.1. Global Pain Management Therapeutics Market Size and Forecast by Region
3.2. Global Pain Management Therapeutics Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing Prevalence of Chronic Diseases around the World
3.3.1.2. Growing number of FDA approvals coupled with launch of new products
3.3.1.3. Growing demand in Emerging economies
3.3.1.4. Increasing geriatric population around the world
3.3.2. Market Restraints
3.3.2.1. Adherence to Stringent Regulatory Norms
3.3.2.2. High Cost of development
3.3.2.3. Product Recall
3.3.3. Opportunities
3.3.3.1. Increasing therapeutic Advancements in Pain Management Therapeutics
3.3.3.2. Huge Untapped Potential in Emerging Markets
3.3.4. Challenges
3.3.4.1. Requirement of high investment for storage and transportation
3.3.4.2. Increasing number of competitor in the market
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Pain Management Therapeutics Market Analysis and Forecast 2021-2031, By Drug Class (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. NSAIDS
4.1.1.1. NSAIDS market size and forecast, 2021-2031 (USD Million)
4.1.2. Anesthetics
4.1.2.1. Anesthetics market size and forecast, 2021-2031 (USD Million)
4.1.3. Anticonvulsants
4.1.3.1. Anticonvulsants market size and forecast, 2021-2031 (USD Million)
4.1.4. Antimigraine Drug
4.1.4.1. Antimigraine Drug market size and forecast, 2021-2031 (USD Million)
4.1.5. Antidepressant Drugs
4.1.5.1. Antidepressant Drugs market size and forecast, 2021-2031 (USD Million)
4.1.6. Opioids
4.1.6.1. Opioids market size and forecast, 2021-2031 (USD Million)
4.1.7. Non-narcotic Analgesics
4.1.7.1. Non-narcotic Analgesics market size and forecast, 2021-2031 (USD Million)
4.1.8. Others
4.1.8.1. Others market size and forecast, 2021-2031 (USD Million)
5. Global Pain Management Therapeutics Market Analysis and Forecast, 2021-2031 By Indication (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Arthritic Pain
5.1.1.1. Arthritic Pain market size and forecast, 2021-2031 (USD Million)
5.1.2. Neuropathic Pain
5.1.2.1. Neuropathic Pain market size and forecast, 2021-2031 (USD Million)
5.1.3. Cancer Pain
5.1.3.1. Cancer Pain market size and forecast, 2021-2031 (USD Million)
5.1.4. Chronic back Pain
5.1.4.1. Chronic back Pain market size and forecast, 2021-2031 (USD Million)
5.1.5. Post-operative Pain
5.1.5.1. Post-operative Pain market size and forecast, 2021-2031 (USD Million)
5.1.6. Migraine
5.1.6.1. Migraine market size and forecast, 2021-2031 (USD Million)
5.1.7. Fibromyalgia
5.1.7.1. Fibromyalgia market size and forecast, 2021-2031 (USD Million)
5.1.8. Bone fracture
5.1.8.1. Bone fracture market size and forecast, 2021-2031 (USD Million)
5.1.9. Muscle sprain/strain
5.1.9.1. Muscle sprain/strain market size and forecast, 2021-2031 (USD Million)
5.1.10. Acute appendicitis
5.1.10.1. Acute appendicitis market size and forecast, 2021-2031 (USD Million)
5.1.11. Others
5.1.11.1. Others market size and forecast, 2021-2031 (USD Million)
6. Global Pain Management Therapeutics Market Analysis and Forecast, 2021-2031 By Drug Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Generic drugs
6.1.1.1. Generic drugs market size and forecast, 2021-2031 (USD Million)
6.1.2. Branded Drugs
6.1.2.1. Branded Drugs market size and forecast, 2021-2031 (USD Million)
7. Global Pain Management Therapeutics Market Analysis and Forecast, 2021-2031 by End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Hospitals
7.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
7.1.2. Homecare
7.1.2.1. Homecare market size and forecast, 2021-2031 (USD Million)
7.1.3. Specialty Clinics
7.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
7.1.4. Others
7.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
8. Global Pain Management Therapeutics Market Analysis and Forecast, 2021-2031 by Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Hospitals Pharmacy
8.1.1.1. Hospitals Pharmacy Market size and forecast, 2021-2031 (USD Million)
8.1.2. Retail Pharmacy
8.1.2.1. Retail Pharmacy market size and forecast, 2021-2031 (USD Million)
8.1.3. Ecommerce
8.1.3.1. Ecommerce market size and forecast, 2021-2031 (USD Million)
8.1.4. Others
8.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
9. North America Pain Management Therapeutics Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. North America Pain Management Therapeutics Market Size and Forecast By Drug Class
9.2.1.1. XX Driving/Opportunity Factor
9.2.1.2. XX Driving/Opportunity Factor
9.3. North America Pain Management Therapeutics Market Size and Forecast By Indication
9.3.1.1. XX Driving/Opportunity Factor
9.3.1.2. XX Driving/Opportunity Factor
9.4. North America Pain Management Therapeutics Market Size and Forecast By Drug Type
9.4.1.1. XX Driving/Opportunity Factor
9.4.1.2. XX Driving/Opportunity Factor
9.5. North America Pain Management Therapeutics Market Size and Forecast By End-User
9.5.1.1. XX Driving/Opportunity Factor
9.5.1.2. XX Driving/Opportunity Factor
9.6. North America Pain Management Therapeutics Market Size and Forecast By Distribution Channel
9.6.1.1. XX Driving/Opportunity Factor
9.6.1.2. XX Driving/Opportunity Factor
9.7. U.S. Pain Management Therapeutics Market
9.7.1.1. XX Driving/Opportunity Factor
9.7.1.2. XX Driving/Opportunity Factor
9.8. Canada Pain Management Therapeutics Market
9.8.1.1. XX Driving/Opportunity Factor
9.8.1.2. XX Driving/Opportunity Factor
10. Europe Pain Management Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Europe Pain Management Therapeutics Market Size and Forecast By Drug Class
10.2.1.1. XX Driving/Opportunity Factor
10.2.1.2. XX Driving/Opportunity Factor
10.3. Europe Pain Management Therapeutics Market Size and Forecast By Indication
10.3.1.1. XX Driving/Opportunity Factor
10.3.1.2. XX Driving/Opportunity Factor
10.4. Europe Pain Management Therapeutics Market Size and Forecast By Drug Type
10.4.1.1. XX Driving/Opportunity Factor
10.4.1.2. XX Driving/Opportunity Factor
10.5. Europe Pain Management Therapeutics Market Size and Forecast By End-User
10.5.1.1. XX Driving/Opportunity Factor
10.5.1.2. XX Driving/Opportunity Factor
10.6. Europe Pain Management Therapeutics Market Size and Forecast By Distribution Channel
10.6.1.1. XX Driving/Opportunity Factor
10.6.1.2. XX Driving/Opportunity Factor
10.7. UK Pain Management Therapeutics Market
10.7.1.1. XX Driving/Opportunity Factor
10.7.1.2. XX Driving/Opportunity Factor
10.8. Germany Pain Management Therapeutics Market
10.8.1.1. XX Driving/Opportunity Factor
10.8.1.2. XX Driving/Opportunity Factor
10.9. France Pain Management Therapeutics Market
10.9.1.1. XX Driving/Opportunity Factor
10.9.1.2. XX Driving/Opportunity Factor
10.10. Rest of Europe Pain Management Therapeutics Market
10.10.1.1. XX Driving/Opportunity Factor
10.10.1.2. XX Driving/Opportunity Factor
11. Asia Pacific Pain Management Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. Asia-Pacific Pain Management Therapeutics Market Size and Forecast By Drug Class
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. Asia-Pacific Pain Management Therapeutics Market Size and Forecast By Indication
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. Asia-Pacific Pain Management Therapeutics Market Size and Forecast By Drug Type
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. Asia-Pacific Pain Management Therapeutics Market Size and Forecast By End-User
11.5.1.1. XX Driving/Opportunity Factor
11.5.1.2. XX Driving/Opportunity Factor
11.6. Asia-Pacific Pain Management Therapeutics Market Size and Forecast By Distribution Channel
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. China Pain Management Therapeutics Market
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. India Pain Management Therapeutics Market
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
11.9. Japan Pain Management Therapeutics Market
11.9.1.1. XX Driving/Opportunity Factor
11.9.1.2. XX Driving/Opportunity Factor
11.10. Rest of Asia Pacific Pain Management Therapeutics Market
11.10.1.1. XX Driving/Opportunity Factor
11.10.1.2. XX Driving/Opportunity Factor
12. Latin America Pain Management Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. Latin America Pain Management Therapeutics Market Size and Forecast By Drug Class
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. Latin America Pain Management Therapeutics Market Size and Forecast By Indication
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. Latin America Pain Management Therapeutics Market Size and Forecast By Drug Type
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. Latin America Pain Management Therapeutics Market Size and Forecast By End-User
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. Latin America Pain Management Therapeutics Market Size and Forecast By Distribution Channel
12.7. Brazil Pain Management Therapeutics Market
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. Mexico Pain Management Therapeutics Market
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. Rest of Latin America Pain Management Therapeutics Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
13. MEA Pain Management Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. MEA Pain Management Therapeutics Market Size and Forecast By Drug Class
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. MEA Pain Management Therapeutics Market Size and Forecast By Indication
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. MEA Pain Management Therapeutics Market Size and Forecast By Drug Type
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. MEA Pain Management Therapeutics Market Size and Forecast By End-User
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. MEA Pain Management Therapeutics Market Size and Forecast By Distribution Channel
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. GCC Pain Management Therapeutics Market
13.7.1.1. XX Driving/Opportunity Factor
13.7.1.2. XX Driving/Opportunity Factor
13.8. South Africa Pain Management Therapeutics Market
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. Rest of MEA Pain Management Therapeutics Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
14. Companies in the Pain Management Therapeutics Market
14.1. Abbott Laboratories
14.1.1. Company Snapshot
14.1.2. Company Overview
14.1.3. Financial Performance (2015-2019)
14.1.3.1. Net Revenue
14.1.3.2. Gross Profit
14.1.3.3. Geographical Revenue, 2019
14.1.4. Product Offerings
14.1.5. Recent Initiatives (2017-2019)
14.2. Eli Lily And Company
14.2.1. Company Snapshot
14.2.2. Company Overview
14.2.3. Financial Performance (2015-2019)
14.2.3.1. Net Revenue
14.2.3.2. Gross Profit
14.2.3.3. Geographical Revenue, 2019
14.2.4. Product Offerings
14.2.5. Recent Initiatives (2017-2019)
14.3. Endo Health Solutions, Inc. (Endo International Plc.)
14.3.1. Company Snapshot
14.3.2. Company Overview
14.3.3. Financial Performance (2015-2019)
14.3.3.1. Net Revenue
14.3.3.2. Gross Profit
14.3.3.3. Geographical Revenue, 2019
14.3.4. Product Offerings
14.3.5. Recent Initiatives (2017-2019)
14.4. Glaxosmithkline Plc (GSK)
14.4.1. Company Snapshot
14.4.2. Company Overview
14.4.3. Financial Performance (2015-2019)
14.4.3.1. Net Revenue
14.4.3.2. Gross Profit
14.4.3.3. Geographical Revenue, 2019
14.4.4. Product Offerings
14.4.5. Recent Initiatives (2017-2019)
14.5. Johnson & Johnson
14.5.1. Company Snapshot
14.5.2. Company Overview
14.5.3. Financial Performance (2015-2019)
14.5.3.1. Net Revenue
14.5.3.2. Gross Profit
14.5.3.3. Geographical Revenue, 2019
14.5.4. Product Offerings
14.5.5. Recent Initiatives (2017-2019)
14.6. Merck & Co., Inc.
14.6.1. Company Snapshot
14.6.2. Company Overview
14.6.3. Financial Performance (2015-2019)
14.6.3.1. Net Revenue
14.6.3.2. Gross Profit
14.6.3.3. Geographical Revenue, 2019
14.6.4. Product Offerings
14.6.5. Recent Initiatives (2017-2019)
14.7. Mylan N.V.
14.7.1. Company Snapshot
14.7.2. Company Overview
14.7.3. Financial Performance (2015-2019)
14.7.3.1. Net Revenue
14.7.3.2. Gross Profit
14.7.3.3. Geographical Revenue, 2019
14.7.4. Product Offerings
14.7.5. Recent Initiatives (2017-2019)
14.8. Merck & Co.
14.8.1. Company Snapshot
14.8.2. Company Overview
14.8.3. Financial Performance (2015-2019)
14.8.3.1. Net Revenue
14.8.3.2. Gross Profit
14.8.3.3. Geographical Revenue, 2019
14.8.4. Product Offerings
14.8.5. Recent Initiatives (2017-2019)
14.9. Novartis
14.9.1. Company Snapshot
14.9.2. Company Overview
14.9.3. Financial Performance (2015-2019)
14.9.3.1. Net Revenue
14.9.3.2. Gross Profit
14.9.3.3. Geographical Revenue, 2019
14.9.4. Product Offerings
14.9.5. Recent Initiatives (2017-2019)
14.10. Pfizer
14.10.1. Company Snapshot
14.10.2. Company Overview
14.10.3. Financial Performance (2015-2019)
14.10.3.1. Net Revenue
14.10.3.2. Gross Profit
14.10.3.3. Geographical Revenue, 2019
14.10.4. Product Offerings
14.10.5. Recent Initiatives (2017-2019)
14.11. Other Notable Players
15. Conclusion
16. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Pain Management Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Pain Management Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Pain Management Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Pain Management Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Pain Management Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Pain Management Therapeutics Market Drivers & Restraints 2021
Table 7. Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. NSAIDS Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. NSAIDS Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. NSAIDS Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. NSAIDS Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. NSAIDS Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Anesthetics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Anesthetics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Anesthetics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Anesthetics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Anesthetics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Anticonvulsants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Anticonvulsants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Anticonvulsants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Anticonvulsants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Anticonvulsants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Antimigraine Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Antimigraine Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Antimigraine Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Antimigraine Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Antimigraine Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Antidepressant Drugs Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 33. Antidepressant Drugs Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Antidepressant Drugs Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Antidepressant Drugs Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Antidepressant Drugs Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Non-narcotic Analgesics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Non-narcotic Analgesics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Non-narcotic Analgesics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Non-narcotic Analgesics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Non-narcotic Analgesics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Arthritic PainForecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Arthritic PainForecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Arthritic PainForecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Arthritic PainForecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Arthritic PainForecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Neuropathic Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Neuropathic Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Neuropathic Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Neuropathic Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Neuropathic Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Cancer Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Cancer Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Cancer Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Cancer Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Cancer Pain h Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Chronic back Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Chronic back Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Chronic back Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Chronic back Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Chronic back Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Post-operative Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Post-operative Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Post-operative Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Post-operative Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Post-operative Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Migraine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Migraine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Migraine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Migraine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Migraine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Fibromyalgia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Fibromyalgia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Fibromyalgia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Fibromyalgia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Fibromyalgia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Bone Fracture Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Bone Fracture Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Bone Fracture Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Bone Fracture Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Bone Fracture Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Muscle Sprain/Strain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Muscle Sprain/Strain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Muscle Sprain/Strain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Muscle Sprain/Strain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Muscle Sprain/Strain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L) Acute Appendicitis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 97. Acute Appendicitis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 98. Acute Appendicitis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 99. Acute Appendicitis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 100. Acute Appendicitis h Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 101. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 102. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 103. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 104. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 105. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 106. Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 107. Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 108. Pain Management Therapeutics Market Forecast by Drug Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 109. Pain Management Therapeutics Market Forecast by Drug Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 110. Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 111. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 112. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 113. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 114. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 115. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 116. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 117. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 118. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 119. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 120. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 121. Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 122. Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 123. Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 124. Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 125. Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 126. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 127. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 128. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 129. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 130. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 131. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 132. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 133. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 134. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 135. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 136. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 137. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 138. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 139. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 140. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 141. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 142. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 143. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 144. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 145. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 146. Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 147. Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 148. Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 149. Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 150. Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 151. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 152. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 153. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 154. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 155. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 156. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 157. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 158. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 159. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 160. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 161. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 162. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 163. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 164. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 165. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 166. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 167. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 168. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 169. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 170. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 171. North America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 172. North America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 173. North America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 174. North America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 175. North America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 176. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 177. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 178. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 179. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 180. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 181. North America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 182. North America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 183. North America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 184. North America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 185. North America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 186. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 187. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 188. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 189. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 190. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 191. North America Pain Management Therapeutics Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 192. North America Pain Management Therapeutics Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 193. North America Pain Management Therapeutics Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 194. North America Pain Management Therapeutics Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 195. North America Pain Management Therapeutics Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 196. North America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 197. North America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 198. North America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 199. North America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 200. North America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 201. North America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 202. North America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 203. North America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 204. North America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 205. North America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 206. North America Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 207. North America Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 208. North America Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 209. North America Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 210. North America Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 211. US Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 212. US Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 213. US Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 214. US Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 215. US Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 216. Canada Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 217. Canada Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 218. Canada Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 219. Canada Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 220. Canada Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 221. Europe Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 222. Europe Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 223. Europe Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 224. Europe Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 225. Europe Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 226. Europe Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 227. Europe Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 228. Europe Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 229. Europe Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 230. Europe Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 231. Europe Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 232. Europe Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 233. Europe Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 234. Europe Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 235. Europe Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 236. Europe Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 237. Europe Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 238. Europe Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 239. Europe Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 240. Europe Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 241. Europe Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 242. Europe Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 243. Europe Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 244. Europe Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 245. Europe Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 246. Europe Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 247. Europe Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 248. Europe Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 249. Europe Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 250. UK Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 251. UK Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 252. UK Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 253. UK Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 254. UK Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 255. Germany Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 256. Germany Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 257. Germany Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 258. Germany Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 259. Germany Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 260. France Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 261. France Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 262. France Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 263. France Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 264. France Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 265. Rest of Europe Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 266. Rest of Europe Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 267. Rest of Europe Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 268. Rest of Europe Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 269. Rest of Europe Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 270. Asia Pacific Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 271. Asia Pacific Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 272. Asia Pacific Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 273. Asia Pacific Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 274. Asia Pacific Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 275. Asia Pacific Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 276. Asia Pacific Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 277. Asia Pacific Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 278. Asia Pacific Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 279. Asia Pacific Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 280. Asia Pacific Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 281. Asia Pacific Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 282. Asia Pacific Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 283. Asia Pacific Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 284. Asia Pacific Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 285. Asia Pacific Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 286. Asia Pacific Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 287. Asia Pacific Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 288. Asia Pacific Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 289. Asia Pacific Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 290. Asia Pacific Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 291. Asia Pacific Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 292. Asia Pacific Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 293. Asia Pacific Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 294. Asia Pacific Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 295. Asia Pacific Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 296. Asia Pacific Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 297. Asia Pacific Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 298. Asia Pacific Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 299. Asia Pacific Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 300. China Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 301. China Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 302. China Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 303. China Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 304. China Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 305. India Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 306. India Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 307. India Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 308. India Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 309. India Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 310. Japan Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 311. Japan Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 312. Japan Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 313. Japan Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 314. Japan Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 315. RoAPAC Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 316. RoAPAC Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 317. RoAPAC Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 318. RoAPAC Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 319. RoAPAC Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 320. Middle East Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 321. Middle East Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 322. Middle East Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 323. Middle East Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 324. Middle East Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 325. Middle East Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 326. Middle East Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 327. Middle East Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 328. Middle East Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 329. Middle East Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 330. Middle East Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 331. Middle East Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 332. Middle East Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 333. Middle East Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 334. Middle East Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 335. Middle East Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 336. Middle East Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 337. Middle East Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 338. Middle East Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 339. Middle East Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 340. Middle East Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 341. Middle East Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 342. Middle East Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 343. Middle East Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 344. Middle East Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 345. Latin America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 346. Latin America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 347. Latin America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 348. Latin America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 349. Latin America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 350. Latin America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 351. Latin America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 352. Latin America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 353. Latin America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 354. Latin America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 355. Latin America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 356. Latin America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 357. Latin America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 358. Latin America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 359. Latin America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 360. Latin America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 361. Latin America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 362. Latin America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 363. Latin America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 364. Latin America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 365. Latin America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 366. Latin America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 367. Latin America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 368. Latin America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 369. Latin America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 370. Africa Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 371. Africa Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 372. Africa Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 373. Africa Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 374. Africa Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 375. Africa Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 376. Africa Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 377. Africa Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 378. Africa Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 379. Africa Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 380. Africa Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 381. Africa Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 382. Africa Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 383. Africa Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 384. Africa Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 385. Africa Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 386. Africa Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 387. Africa Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 388. Africa Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 389. Africa Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 390. Africa Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 391. Africa Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 392. Africa Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 393. Africa Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 394. Africa Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 395. Leading 10 Pain Management Therapeutics Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 396. Abbott Laboratories Profile 2019 (CEO, HQ, Founded, Website)
Table 397. Abbott Laboratories Pain Management Therapeutics Product Offering (Segment, Product Offerings)
Table 398. Eli Lily And Company Profile 2019 (CEO, HQ, Founded, Website)
Table 399. Eli Lily And Company Pain Management Therapeutics Product Offering (Segment, Product Offerings)
Table 400. Endo Health Solutions, Inc. (Endo International Plc.) Profile 2019 (CEO, HQ, Founded, Website)
Table 401. Endo Health Solutions, Inc. (Endo International Plc.).Pain Management Therapeutics Product Offering (Segment, Product Offerings)
Table 402. Glaxosmithkline Plc (GSK) Profile 2019 (CEO, HQ, Founded, Website)
Table 403. Glaxosmithkline Plc (GSK) Pain Management Therapeutics Product Offering (Segment, Product Offerings)
Table 404. Johnson & Johnson Profile 2019 (CEO, HQ, Founded, Website)
Table 405. Johnson & Johnson Pain Management Therapeutics Product Offering (Segment, Product Offerings)
Table 406. Merck & Co., Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 407. Merck & Co., Inc. Pain Management Therapeutics Product Offering (Segment, Product Offerings)
Table 408. GlaxoSmithKline (GSK) Profile 2019 (CEO, HQ, Founded, Website)
Table 409. GlaxoSmithKline (GSK) Pain Management Therapeutics Product Offering (Segment, Product Offerings)
Table 410. Mylan N.V. Profile 2019 (CEO, HQ, Founded, Website)
Table 411. Mylan N.V Pain Management Therapeutics Product Offering (Segment, Product Offerings)
Table 412. Novartis Profile 2019 (CEO, HQ, Founded, Website)
Table 413. Novartis Pain Management Therapeutics Product Offering (Segment, Product Offerings)
Table 414. Pfizer Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 415. Pfizer Corporation Pain Management Therapeutics Product Offering (Segment, Product Offerings)
Table 416. Other Companies Involved in the Pain Management Therapeutics Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Pain Management Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Pain Management Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Pain Management Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Pain Management Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Pain Management Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Pain Management Therapeutics Market Drivers & Restraints 2021
Figure 7. Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. NSAIDS Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. NSAIDS Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. NSAIDS Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. NSAIDS Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. NSAIDS Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Anesthetics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Anesthetics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Anesthetics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Anesthetics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Anesthetics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Anticonvulsants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Anticonvulsants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Anticonvulsants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Anticonvulsants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Anticonvulsants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Antimigraine Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Antimigraine Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Antimigraine Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Antimigraine Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Antimigraine Drug Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Antidepressant Drugs Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 33. Antidepressant Drugs Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Antidepressant Drugs Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Antidepressant Drugs Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Antidepressant Drugs Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Non-narcotic Analgesics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Non-narcotic Analgesics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Non-narcotic Analgesics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Non-narcotic Analgesics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Non-narcotic Analgesics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Arthritic PainForecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Arthritic PainForecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Arthritic PainForecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Arthritic PainForecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Arthritic PainForecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Neuropathic Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Neuropathic Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Neuropathic Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Neuropathic Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Neuropathic Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Cancer Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Cancer Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Cancer Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Cancer Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Cancer Pain h Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Chronic back Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Chronic back Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Chronic back Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Chronic back Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Chronic back Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Post-operative Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Post-operative Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Post-operative Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Post-operative Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Post-operative Pain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Migraine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Migraine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Migraine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Migraine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Migraine Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Fibromyalgia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Fibromyalgia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Fibromyalgia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Fibromyalgia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Fibromyalgia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Bone Fracture Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Bone Fracture Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Bone Fracture Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Bone Fracture Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Bone Fracture Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Muscle Sprain/Strain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Muscle Sprain/Strain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Muscle Sprain/Strain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Muscle Sprain/Strain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Muscle Sprain/Strain Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L) Acute Appendicitis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 97. Acute Appendicitis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 98. Acute Appendicitis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 99. Acute Appendicitis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 100. Acute Appendicitis h Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 101. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 102. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 103. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 104. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 105. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 106. Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 107. Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 108. Pain Management Therapeutics Market Forecast by Drug Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 109. Pain Management Therapeutics Market Forecast by Drug Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 110. Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 111. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 112. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 113. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 114. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 115. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 116. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 117. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 118. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 119. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 120. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 121. Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 122. Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 123. Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 124. Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 125. Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 126. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 127. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 128. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 129. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 130. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 131. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 132. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 133. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 134. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 135. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 136. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 137. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 138. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 139. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 140. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 141. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 142. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 143. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 144. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 145. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 146. Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 147. Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 148. Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 149. Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 150. Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 151. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 152. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 153. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 154. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 155. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 156. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 157. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 158. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 159. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 160. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 161. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 162. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 163. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 164. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 165. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 166. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 167. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 168. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 169. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 170. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 171. North America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 172. North America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 173. North America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 174. North America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 175. North America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 176. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 177. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 178. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 179. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 180. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 181. North America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 182. North America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 183. North America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 184. North America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 185. North America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 186. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 187. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 188. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 189. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 190. North America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 191. North America Pain Management Therapeutics Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 192. North America Pain Management Therapeutics Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 193. North America Pain Management Therapeutics Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 194. North America Pain Management Therapeutics Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 195. North America Pain Management Therapeutics Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 196. North America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 197. North America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 198. North America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 199. North America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 200. North America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 201. North America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 202. North America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 203. North America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 204. North America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 205. North America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 206. North America Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 207. North America Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 208. North America Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 209. North America Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 210. North America Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 211. US Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 212. US Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 213. US Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 214. US Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 215. US Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 216. Canada Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 217. Canada Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 218. Canada Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 219. Canada Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 220. Canada Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 221. Europe Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 222. Europe Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 223. Europe Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 224. Europe Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 225. Europe Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 226. Europe Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 227. Europe Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 228. Europe Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 229. Europe Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 230. Europe Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 231. Europe Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 232. Europe Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 233. Europe Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 234. Europe Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 235. Europe Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 236. Europe Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 237. Europe Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 238. Europe Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 239. Europe Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 240. Europe Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 241. Europe Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 242. Europe Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 243. Europe Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 244. Europe Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 245. Europe Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 246. Europe Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 247. Europe Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 248. Europe Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 249. Europe Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 250. UK Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 251. UK Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 252. UK Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 253. UK Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 254. UK Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 255. Germany Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 256. Germany Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 257. Germany Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 258. Germany Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 259. Germany Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 260. France Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 261. France Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 262. France Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 263. France Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 264. France Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 265. Rest of Europe Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 266. Rest of Europe Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 267. Rest of Europe Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 268. Rest of Europe Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 269. Rest of Europe Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 270. Asia Pacific Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 271. Asia Pacific Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 272. Asia Pacific Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 273. Asia Pacific Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 274. Asia Pacific Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 275. Asia Pacific Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 276. Asia Pacific Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 277. Asia Pacific Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 278. Asia Pacific Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 279. Asia Pacific Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 280. Asia Pacific Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 281. Asia Pacific Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 282. Asia Pacific Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 283. Asia Pacific Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 284. Asia Pacific Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 285. Asia Pacific Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 286. Asia Pacific Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 287. Asia Pacific Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 288. Asia Pacific Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 289. Asia Pacific Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 290. Asia Pacific Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 291. Asia Pacific Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 292. Asia Pacific Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 293. Asia Pacific Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 294. Asia Pacific Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 295. Asia Pacific Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 296. Asia Pacific Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 297. Asia Pacific Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 298. Asia Pacific Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 299. Asia Pacific Pain Management Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 300. China Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 301. China Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 302. China Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 303. China Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 304. China Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 305. India Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 306. India Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 307. India Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 308. India Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 309. India Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 310. Japan Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 311. Japan Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 312. Japan Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 313. Japan Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 314. Japan Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 315. RoAPAC Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 316. RoAPAC Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 317. RoAPAC Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 318. RoAPAC Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 319. RoAPAC Pain Management Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 320. Middle East Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 321. Middle East Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 322. Middle East Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 323. Middle East Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 324. Middle East Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 325. Middle East Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 326. Middle East Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 327. Middle East Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 328. Middle East Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 329. Middle East Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 330. Middle East Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 331. Middle East Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 332. Middle East Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 333. Middle East Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 334. Middle East Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 335. Middle East Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 336. Middle East Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 337. Middle East Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 338. Middle East Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 339. Middle East Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 340. Middle East Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 341. Middle East Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 342. Middle East Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 343. Middle East Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 344. Middle East Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 345. Latin America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 346. Latin America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 347. Latin America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 348. Latin America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 349. Latin America Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 350. Latin America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 351. Latin America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 352. Latin America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 353. Latin America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 354. Latin America Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 355. Latin America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 356. Latin America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 357. Latin America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 358. Latin America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 359. Latin America Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 360. Latin America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 361. Latin America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 362. Latin America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 363. Latin America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 364. Latin America Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 365. Latin America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 366. Latin America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 367. Latin America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 368. Latin America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 369. Latin America Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 370. Africa Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 371. Africa Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 372. Africa Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 373. Africa Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 374. Africa Pain Management Therapeutics Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 375. Africa Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 376. Africa Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 377. Africa Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 378. Africa Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 379. Africa Pain Management Therapeutics Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 380. Africa Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 381. Africa Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 382. Africa Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 383. Africa Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 384. Africa Pain Management Therapeutics Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 385. Africa Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 386. Africa Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 387. Africa Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 388. Africa Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 389. Africa Pain Management Therapeutics Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 390. Africa Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 391. Africa Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 392. Africa Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 393. Africa Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 394. Africa Pain Management Therapeutics Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 395.
Figure 396. Porter’s Five Force Analysis
Companies Mentioned
1. AbbVie
2. Achaogen
3. Actavis
4. Actelion
5. Affinium Pharmaceutical
6. AiCuris GmbH & Co. KG
7. Alcon
8. Alkem Laboratories
9. Allergan
10. Allied Pharma
11. Apotex
12. APP Pharmaceuticals
13. Aptalis Pharma
14. Aquapharm Biodiscovery
15. Cempra Pharmaceuticals
16. Cipla
17. Claris Lifesciences
18. Cornerstone Biopharma
19. Cornerstone Therapeutics
20. Corona Remedies
21. Eli Lilly
22. Gate Pharma
23. Gilead Sciences
24. GlaxoSmithKline (GSK)
25. Glenmark
26. GlycoVaxyn
27. Hetero
28. Hikma Farmaceutica
29. Hi-Tech Pharma
30. Hospira
31. Macleod Pharmaceuticals
32. Microlabs
33. Nalneva
34. Novartis
35. Novexel
36. Paratek Pharmaceuticals
37. Pfizer
38. Ranbaxy
39. Roche
40. Sagent Pharmaceuticals
41. Sandoz
42. Sanofi
43. Sequella
44. Shanghai MengKe Pharmaceuticals
45. Shionogi
46. SHIONOGI Co., Ltd.
47. Shire
48. Sidmak Labs
49. Solitaire Pharmacia
50. Specialised Therapeutics Australia
Companies Profiled in the Report
1. Abbott Laboratories
2. Eli Lily And Company
3. Endo Health Solutions, Inc. (Endo International Plc.)
4. Glaxosmithkline Plc (GSK)
5. Johnson & Johnson
6. Merck & Co., Inc.
7. Mylan N.V.
8. Novartis International Ag
9. Pfizer Inc.
10. Purdue Pharma L.P.
List of Companies Mentioned in the Report:
1. AbbVie
2. Achaogen
3. Actavis
4. Actelion
5. Affinium Pharmaceutical
6. AiCuris GmbH & Co. KG
7. Alcon
8. Alkem Laboratories
9. Allergan
10. Allied Pharma
11. Apotex
12. APP Pharmaceuticals
13. Aptalis Pharma
14. Aquapharm Biodiscovery
15. Cempra Pharmaceuticals
16. Cipla
17. Claris Lifesciences
18. Cornerstone Biopharma
19. Cornerstone Therapeutics
20. Corona Remedies
21. Eli Lilly
22. Gate Pharma
23. Gilead Sciences
24. GlaxoSmithKline (GSK)
25. Glenmark
26. GlycoVaxyn
27. Hetero
28. Hikma Farmaceutica
29. Hi-Tech Pharma
30. Hospira
31. Macleod Pharmaceuticals
32. Microlabs
33. Nalneva
34. Novartis
35. Novexel
36. Paratek Pharmaceuticals
37. Pfizer
38. Ranbaxy
39. Roche
40. Sagent Pharmaceuticals
41. Sandoz
42. Sanofi
43. Sequella
44. Shanghai MengKe Pharmaceuticals
45. Shionogi
46. SHIONOGI Co., Ltd.
47. Shire
48. Sidmak Labs
49. Solitaire Pharmacia
50. Specialised Therapeutics Australia
List of Organizations Mentioned in the Report:
1. Centre for Pharmaceutical Administration Health Sciences Authority
2. Central Drug Standard Control Organization (CDSCO)
3. Organisation for Economic Co-operation and Development (OECD)
4. European Medicines Agency (EMA)
5. Food and Drug Administration (FDA)
6. National Institutes of Health (NIH)
7. United Nations (UN)
8. United Nations Office on Drugs and Crime (UNODC)
9. United Nations Statistics Division (UNSD)
10. Statistical Office of the European Union (EUROSTAT)
11. University of Connecticut
12. World Health Organization (WHO)
13. The National Medical Products Administration (NMPA)
14. Indian Council of Medical Research (ICMR)
15. The Therapeutic Goods Administration
16. The Federal Institute for Drugs and Medical Devices (BfArM)
17. Pharmaceuticals and Medical Devices Agency (PMDA)
18. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
19. Ministry of Health, Labour & Welfare(MHLW)
20. Medicines and Healthcare Products Regulatory Agency (MHRA)
1. Abbott Laboratories
2. Eli Lily And Company
3. Endo Health Solutions, Inc. (Endo International Plc.)
4. Glaxosmithkline Plc (GSK)
5. Johnson & Johnson
6. Merck & Co., Inc.
7. Mylan N.V.
8. Novartis International Ag
9. Pfizer Inc.
10. Purdue Pharma L.P.
List of Companies Mentioned in the Report:
1. AbbVie
2. Achaogen
3. Actavis
4. Actelion
5. Affinium Pharmaceutical
6. AiCuris GmbH & Co. KG
7. Alcon
8. Alkem Laboratories
9. Allergan
10. Allied Pharma
11. Apotex
12. APP Pharmaceuticals
13. Aptalis Pharma
14. Aquapharm Biodiscovery
15. Cempra Pharmaceuticals
16. Cipla
17. Claris Lifesciences
18. Cornerstone Biopharma
19. Cornerstone Therapeutics
20. Corona Remedies
21. Eli Lilly
22. Gate Pharma
23. Gilead Sciences
24. GlaxoSmithKline (GSK)
25. Glenmark
26. GlycoVaxyn
27. Hetero
28. Hikma Farmaceutica
29. Hi-Tech Pharma
30. Hospira
31. Macleod Pharmaceuticals
32. Microlabs
33. Nalneva
34. Novartis
35. Novexel
36. Paratek Pharmaceuticals
37. Pfizer
38. Ranbaxy
39. Roche
40. Sagent Pharmaceuticals
41. Sandoz
42. Sanofi
43. Sequella
44. Shanghai MengKe Pharmaceuticals
45. Shionogi
46. SHIONOGI Co., Ltd.
47. Shire
48. Sidmak Labs
49. Solitaire Pharmacia
50. Specialised Therapeutics Australia
List of Organizations Mentioned in the Report:
1. Centre for Pharmaceutical Administration Health Sciences Authority
2. Central Drug Standard Control Organization (CDSCO)
3. Organisation for Economic Co-operation and Development (OECD)
4. European Medicines Agency (EMA)
5. Food and Drug Administration (FDA)
6. National Institutes of Health (NIH)
7. United Nations (UN)
8. United Nations Office on Drugs and Crime (UNODC)
9. United Nations Statistics Division (UNSD)
10. Statistical Office of the European Union (EUROSTAT)
11. University of Connecticut
12. World Health Organization (WHO)
13. The National Medical Products Administration (NMPA)
14. Indian Council of Medical Research (ICMR)
15. The Therapeutic Goods Administration
16. The Federal Institute for Drugs and Medical Devices (BfArM)
17. Pharmaceuticals and Medical Devices Agency (PMDA)
18. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
19. Ministry of Health, Labour & Welfare(MHLW)
20. Medicines and Healthcare Products Regulatory Agency (MHRA)
Download sample pages
Complete the form below to download your free sample pages for Pain Management Therapeutics Market Report 2021-2031Download sample pages
Complete the form below to download your free sample pages for Pain Management Therapeutics Market Report 2021-2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033
The global Allergy Immunotherapy market is projected to grow at a CAGR of 7.6% by 2033
31 May 2023
Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
26 May 2023
Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033
The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033
24 May 2023
Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033
The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033
23 May 2023
